Recombinant RSV (Felvizumab Biosimilar) antibody

Catalog No. ABIN5668206

Product Details anti-RSV (Felvizumab Biosimilar) Antibody

Target: RSV (Felvizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Respiratory Syncytial Virus (RSV)

Host: Human

Clonality: Monoclonal

Conjugate: This RSV (Felvizumab Biosimilar) antibody is un-conjugated

Application: ELISA, Functional Studies (Func)

Specificity: This antibody is specific for the conserved fusion (F) protein of RSV.

Characteristics:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Purification: Purified antibody.

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.

Clone: RSHZ19

Isotype: IgG1 kappa

Application Details

Application Notes: Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

Restrictions: For Research Use only

Handling

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for RSV (Felvizumab Biosimilar)

Target: RSV (Felvizumab Biosimilar)

Abstract: RSV (Felvizumab Biosimilar) Products

Target Type: Biosimilar

Background: SB 209763, respiratory syncytial virus